How To interpret results from Next Generation Sequencing reports?

In this educational video of the 'How To' series, Christophe Le Tourneau explains when to test, how to interpret the results from Next Generation Sequencing reports and manage patients expectations. In the metastatic setting NGS can be helpful to identify molecular alterations and then direct patients to the relevant clinical trial. Because of the NGS report complexity, results should always be discussed in a molecular tumour board including a medical oncologist, a pathologist and a biologist.

Reprinted from Lancet Oncology, 16 /13, Le Tourneau C. et al., Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial, Copyright (2015), with permission from Elsevier

Produced by ESMO, https://oncologypro.esmo.org